Advanced search
Start date

Effects of eugenol and its dimer bis-eugenol in inflammatory response in an experimental asthma model

Grant number: 16/20982-0
Support type:Scholarships in Brazil - Scientific Initiation
Effective date (Start): December 01, 2016
Effective date (End): November 30, 2017
Field of knowledge:Biological Sciences - Physiology
Principal Investigator:Carla Máximo Prado
Grantee:Rafael Cossi da Silva
Instituição-sede : Instituto de Saúde e Sociedade (ISS). Universidade Federal de São Paulo (UNIFESP). Campus Baixada Santista. Santos, SP, Brazil


Asthma is a chronic inflammatory airway disease and a public health problem. Even with the existence of treatment and various drugs, there are still a percentage of patients who do not respond to treatment and die or have high morbidity generating high costs to the National Health System. It is common knowledge that plants are used as medicinal treatments since pre-colonial times, and this study attempts to elucidate the mechanisms and the result of using a flavonoid eugenol and also a dimer bis-eugenol in an experimental asthma model. Based on previous studies, eugenol has important anti-inflammatory and our question goes beyond trying to clarify whether its dimer might have better effect in the use of eugenol. Objectives: The aim of this study is to evaluate whether treatment with eugenol and its dimer modulate the inflammatory response and bronchial hyperresponsiveness in an asthma mice model Methodology: Animals will be exposed to ovalbumin (OVA) or saline for 28 days and treated with eugenol, bis-eugenol or dexametasone, from day 22 of the experimental protocol. On the 29th, we will evaluate the dose response curve to methacholine and bronchoalveolar lavage and lung will be collected for determination of cytokines and NF-kB pathway. Our hypothesis is that these treatments attenuate the inflammatory response in asthma, and that eventually the bis-eugenol has a different effect of eugenol, trying to associate the molecular structure of biological activity in this model. (AU)

Articles published in Agência FAPESP about the scholarship:
Nicotinic receptor could be target for treatment of lung inflammation